Related references
Note: Only part of the references are listed.A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling
Sai Krishna Athuluri-Divakar et al.
CELL (2016)
Loss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis
G. Kong et al.
LEUKEMIA (2016)
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Piro Lito et al.
SCIENCE (2016)
Identification of pyrazolopyridazinones as PDEd inhibitors
Bjoern Papke et al.
NATURE COMMUNICATIONS (2016)
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
Matthew P. Patricelli et al.
CANCER DISCOVERY (2016)
K-Ras Promotes Tumorigenicity through Suppression of Non-canonical Wnt Signaling
Man-Tzu Wang et al.
CELL (2015)
Small Molecule Binding Sites on the Ras:SOS Complex Can Be Exploited for Inhibition of Ras Activation
Jon J. G. Winter et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
John C. Hunter et al.
MOLECULAR CANCER RESEARCH (2015)
Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices
Elizaveta S. Leshchiner et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway
Xiaolin Nan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif
Frederick D. Tsai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
GTP-Dependent K-Ras Dimerization
Serena Muratcioglu et al.
STRUCTURE (2015)
Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice
A. Staffas et al.
LEUKEMIA (2015)
Therapeutic Targeting of Oncogenic K-Ras by a Covalent Catalytic Site Inhibitor
Sang Min Lim et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
Oncogenic K-Ras requires activation for enhanced activity
H. Huang et al.
ONCOGENE (2014)
H-Ras forms dimers on membrane surfaces via a protein-protein interface
Wan-Chen Lin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange
Michael C. Burns et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Stabilizing the Pro-Apoptotic BimBH3 Helix (BimSAHB) Does Not Necessarily Enhance Affinity or Biological Activity
Toru Okamoto et al.
ACS CHEMICAL BIOLOGY (2013)
A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation
Carolyn Bentley et al.
BIOCHEMICAL JOURNAL (2013)
Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo
Angell Shieh et al.
BLOOD (2013)
Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance
Esther Castellano et al.
CANCER CELL (2013)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling
Gunther Zimmermann et al.
NATURE (2013)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Andrographolide derivatives inhibit guanine nucleotide exchange and abrogate oncogenic Ras function
Harrison J. Hocker et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction
Fumi Shima et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
NMR-based functional profiling of RASopathies and oncogenic RAS mutations
Matthew J. Smith et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
EGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocarcinoma
Carolina Navas et al.
CANCER CELL (2012)
EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis
Christine M. Ardito et al.
CANCER CELL (2012)
A Comprehensive Survey of Ras Mutations in Cancer
Ian A. Prior et al.
CANCER RESEARCH (2012)
Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity
Till Maurer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Solution Structure of the State 1 Conformer of GTP-bound H-Ras Protein and Distinct Dynamic Properties between the State 1 and State 2 Conformers
Mitsugu Araki et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Mutant K-Ras Activation of the Proapoptotic MST2 Pathway Is Antagonized by Wild-Type K-Ras
David Matallanas et al.
MOLECULAR CELL (2011)
A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK
Damian F. Brennan et al.
NATURE (2011)
An orthosteric inhibitor of the Ras-Sos interaction
Anupam Patgiri et al.
NATURE CHEMICAL BIOLOGY (2011)
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Simon A. Forbes et al.
NUCLEIC ACIDS RESEARCH (2011)
Molecular Predictors of Outcome in a Phase 3 Study of Gemcitabine and Erlotinib Therapy in Patients With Advanced Pancreatic Cancer National Cancer Institute of Canada Clinical Trials Group Study PA 3
Gilda da Cunha Santos et al.
CANCER (2010)
Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival
Matthias Drosten et al.
EMBO JOURNAL (2010)
Structural Basis for Conformational Dynamics of GTP-bound Ras Protein
Fumi Shima et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Allosteric modulation of Ras positions Q61 for a direct role in catalysis
Greg Buhrman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Structural basis for the specific inhibition of heterotrimeric Gq protein by a small molecule
Akiyuki Nishimura et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer
Meng Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Selective cytotoxicity of a bicyclic Ras inhibitor in cancer cells expressing K-RaSG13D
Alessandro Palmioli et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Characterization of a Ras Mutant with Identical GDP- and GTP-Bound Structures
Bradley Ford et al.
BIOCHEMISTRY (2009)
A dimerization-dependent mechanism drives RAF catalytic activation
Thanashan Rajakulendran et al.
NATURE (2009)
Non-steroidal anti-inflammatory drugs suppress the ERK signaling pathway via block of Ras/c-Raf interaction and activation of MAP kinase phosphatases
Mei-Ren Pan et al.
CELLULAR SIGNALLING (2008)
Farnesyltransferase inhibitors: A detailed chemical view on an elusive biological problem
Sergio F. Sousa et al.
CURRENT MEDICINAL CHEMISTRY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Mapping the nucleotide and isoform-dependent structural and dynamical features of ras proteins
Alemayehu A. Gorfe et al.
STRUCTURE (2008)
Reaching for high-hanging fruit in drug discovery at protein-protein interfaces
James A. Wells et al.
NATURE (2007)
Chemical genetics: Where genetics and pharmacology meet
Zachary A. Knight et al.
CELL (2007)
Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome
Marco Tartaglia et al.
NATURE GENETICS (2007)
Germline gain-of-function mutations in SOS1 cause Noonan syndrome
Amy E. Roberts et al.
NATURE GENETICS (2007)
Thrombomodulin tightens the thrombin active site loops to promote protein C activation
JR Koeppe et al.
BIOCHEMISTRY (2005)
Structure of the G60A mutant of Ras
B Ford et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Development of farnesyl transferase inhibitors: A review
NMGM Appels et al.
ONCOLOGIST (2005)
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
W Pao et al.
PLOS MEDICINE (2005)
A novel Gαq/11-selective inhibitor
J Takasaki et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Sulindac-derived Ras pathway inhibitors target the Ras-Raf interaction and downstream effectors in the Ras pathway
H Waldmann et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2004)
Identification of potent Ras signaling inhibitors by pathway-selective phenotype-based screening
O Muller et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2004)
Structural analysis of autoinhibition in the Ras activator son of sevenless
H Sondermann et al.
CELL (2004)
Structural evidence for feedback activation by Ras-GTP of the Ras-specific nucleotide exchange factor SOS
SM Margarit et al.
CELL (2003)
Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells
J Kato-Stankiewicz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Wildtype Kras2 can inhibit lung carcinogenesis in mice
ZQ Zhang et al.
NATURE GENETICS (2001)
Dynamic properties of the Ras switch I region and its importance for binding to effectors
M Spoerner et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase γ
ME Pacold et al.
CELL (2000)
Design and synthesis of a transferable farnesyl pyrophosphate analogue to Ras by protein farnesyltransferase
KAH Chehade et al.
JOURNAL OF ORGANIC CHEMISTRY (2000)
Share Paper
